Genomics profiling provides valuable medical insights to help doctors develop optimal treatment and effective prevention plans.
Cancer is a heterogeneous disease and each cancer is unique. Genomics assays can help detect molecular alterations in DNA that promote cancer growth, proliferation, spreading, and drug resistance. Results from genomics tests help doctors identify optimal personalized therapeutic strategies.
Next-Generation Sequencing and other latest technologies are applied to analyze tumor genomes for all types of genomic changes (insertions and deletions, rearrangements, bases replacements, and copy number variations).
All genomics analysis results will be validated and certified by American medical geneticists/pathologists. In addition, these data will be combined with medical profile revision to generate a comprehensive report.
Comparison of Elsee Genomics Assays
(*): Tumor mutational burden (TMB) is a measurement of tumor genome alterations. TMB helps predict tumor sensitivity to immunotherapies.
(**): Microsatellite Instability (MSI) is the condition of genetic hypermutability resulting from loss of DNA mismatch repair activity. MSI helps predict tumor response to immunotherapies.